The Increasing Weight of Crohn's Disease Subjects in Clinical Trials: A Hypothesis-generatings Time-trend Analysis

被引:71
作者
Moran, Gordon W.
Dubeau, Marie-France
Kaplan, Gilaad G.
Panaccione, Remo
Ghosh, Subrata
机构
[1] Univ Calgary, Dept Med, Inflammatory Bowel Dis Clin, Calgary, AB T2N 2T9, Canada
[2] Univ Calgary, Alberta IBD Consortium, Calgary, AB T2N 2T9, Canada
关键词
obesity; adiposity; Crohn's disease; inflammatory bowel disease; PLACEBO-CONTROLLED TRIAL; NECROSIS-FACTOR-ALPHA; HUMANIZED MONOCLONAL-ANTIBODY; INFLAMMATORY BOWEL DISEASES; DOUBLE-BLIND; CERTOLIZUMAB PEGOL; RANDOMIZED-TRIAL; ORAL BUDESONIDE; INTESTINAL INFLAMMATION; MAINTENANCE THERAPY;
D O I
10.1097/MIB.0b013e31829936a4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background:The incidence of obesity is increasing worldwide. Recent evidence shows that the incidence of Crohn's disease (CD) is increasing as well. Adipocytes release a variety of proinflammatory cytokines and peptides. Visceral adiposity may play an important role in the initiation and perpetuation of inflammation in CD. We report on an analysis of body weight in CD clinical trials between 1991 and 2008.Methods:MEDLINE-based databases were searched for randomized controlled trials pertaining to CD. A time-trend analysis was carried out to investigate changes in weight and disease activity over time. Potential correlation between subject weight and clinical activity was studied.Results:Forty randomized controlled trials involving a total of 10,282 patients with CD conducted between 1991 and 2008 were included. No significant change in gender distribution was noted throughout the follow-up. A significant increase in weight (r(2) = 0.360; 95% confidence interval [CI]: 0.4556-0.8813) and body mass index (r(2) = 0.1431; 95% CI: 0.02628-0.2272) was observed over the time period. Study subjects demonstrated a significant increase in clinical disease activity as measured by the Crohn's disease activity index (r(2) = 0.1092; 95% CI: 2.101-9.087) and disease duration (r(2) = 0.06340; 95% CI: 0.02421-0.2530) over the same time period.Conclusions:We demonstrate increasing body weight over time from 1991 to 2008 in CD as evidenced by baseline data from randomized clinical trials. Adiposity may play a potential role in initiating and perpetuating intestinal inflammation, a hypothesis that should be explored further.
引用
收藏
页码:2949 / 2956
页数:8
相关论文
共 64 条
  • [1] Molodecky Natalie A, 2010, Gastroenterol Hepatol (N Y), V6, P339
  • [2] Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study
    Ardizzone, S
    Bollani, S
    Manzionna, G
    Imbesi, V
    Colombo, E
    Porro, GB
    [J]. DIGESTIVE AND LIVER DISEASE, 2003, 35 (09) : 619 - 627
  • [3] Budesonide versus prednisone in the treatment of active Crohn's disease
    Bar-Meir, S
    Chowers, Y
    Lavy, A
    Abramovitch, D
    Sternberg, A
    Leichtmann, G
    Reshef, R
    Odes, S
    Moshkovitz, M
    Bruck, R
    Eliakim, R
    Maoz, E
    Mittmann, U
    [J]. GASTROENTEROLOGY, 1998, 115 (04) : 835 - 840
  • [4] Leptin-dependent toll-like receptor expression and responsiveness in preadipocytes and adipocytes
    Batra, Arvind
    Pietsch, Jeannette
    Fedke, Inka
    Glauben, Rainer
    Okur, Besir
    Stroh, Thorsten
    Zeitz, Martin
    Siegmund, Britta
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2007, 170 (06) : 1931 - 1941
  • [5] Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases
    Bernstein, Charles N.
    Shanahan, Fergus
    [J]. GUT, 2008, 57 (09) : 1185 - 1191
  • [6] Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease?
    Bhalme, Mahesh
    Sharma, Abhishek
    Keld, Richard
    Willert, Robert
    Campbell, Simon
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2013, 25 (05) : 543 - 549
  • [7] Crohn's disease clinical course and severity in obese patients
    Blain, A
    Cattan, S
    Beaugerie, L
    Carbonnel, F
    Gendre, JP
    Cosnes, J
    [J]. CLINICAL NUTRITION, 2002, 21 (01) : 51 - 57
  • [8] Oral budesonide is as effective as oral prednisolone in active Crohn's disease
    Campieri, M
    Ferguson, A
    Doe, W
    Persson, T
    Nilsson, LG
    Malchow, H
    Prantera, C
    Mani, V
    OMorain, C
    Selby, W
    Pallone, F
    diPietralata, MM
    Sjodahl, R
    Florin, T
    Smith, P
    Bianchi, P
    Lofberg, R
    Rutgeerts, P
    Smallwood, R
    Lamers, HW
    TasmanJones, C
    Hunter, JO
    Hodgson, H
    Danielsson, A
    Lee, FI
    Piacitelli, G
    Giovanni, S
    Ellis, A
    Weir, DG
    [J]. GUT, 1997, 41 (02) : 209 - 214
  • [9] Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
    Colombel, Jean Frederic
    Sandborn, William J.
    Reinisch, Walter
    Mantzaris, Gerassimos J.
    Kornbluth, Asher
    Rachmilewitz, Daniel
    Lichtiger, Simon
    D'Haens, Geert
    Diamond, Robert H.
    Broussard, Delma L.
    Tang, Kezhen L.
    van der Woude, C. Janneke
    Rutgeerts, Paul
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (15) : 1383 - 1395
  • [10] Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
    Colombel, Jean-Frederic
    Sandborn, William J.
    Rutgeerts, Paul
    Enns, Robert
    Hanauer, Stephen B.
    Panaccione, Remo
    Schreiber, Stefan
    Byczkowski, Dan
    Li, Ju
    Kent, Jeffrey D.
    Pollack, Paul F.
    [J]. GASTROENTEROLOGY, 2007, 132 (01) : 52 - 65